In conclusion, this small retrospective cohort suggests ipilimumab might enhance and reboost immune response in patients with advanced NSCLC progressing on anti‐PD‐1/PD‐L1 therapy, while delaying exposure to the higher rates of irAE associated with upfront combination therapy. Here, CD274 is linked to non-small cell lung carcinoma.